Open Access iconOpen Access

ARTICLE

crossmark

A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells

EUN SOOK KIM1, SANGHEE KIM2, AREE MOON1,*

1 Duksung Innovative Drug Center, College of Pharmacy, Duksung Women’s University, Seoul, 03169, Korea
2 College of Pharmacy, Seoul National University, Seoul, 08826, Korea

* Corresponding Author: AREE MOON. Email: email

Oncology Research 2023, 31(6), 867-875. https://doi.org/10.32604/or.2023.030411

Abstract

Invasion and metastasis are important hallmarks of breast cancer and are the leading cause of patient mortality. Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer characterized by a poor prognosis and a lack of effective targeted therapies. The present study investigated the inhibitory effect of a novel FTY720 derivative on the invasive phenotype of TNBC cells. Here, we showed that a novel compound with an isoxazole ring, 4-(3-Decylisoxazol-5-yl)-1-hydroxy-2-(hydroxymethyl)butan-2-aminium chloride (CM2-II-173), significantly inhibited invasiveness of MDA-MB-231 TNBC cells. Expression of matrix metalloproteinase (MMP)-9 and invasiveness of MCF10A normal breast cells induced by sphingosine-1-phosphate (S1P) were reduced by CM2-II-173 treatment. Activations of pMEK1, pAkt, pERK, and p38 MAPK by S1P were inhibited by treatment with CM2-II-173. Proliferation and anchorage-independent growth of MDA-MB-231 TNBC cells were significantly decreased by CM2-II-173. CM2-II-173 efficiently induced apoptosis in MDA-MB-231 TNBC cells. CM2-II-173 significantly inhibited invasive phenotypes of breast, liver, prostate, and ovarian cancer cells. CM2-II-173 exhibited a more potent effect on the invasiveness of MDA-MB-231 TNBC cells compared to FTY720. Taken together, this study demonstrated that CM2-II-173 has the potential to be a lead compound that can inhibit cancer progression of not only TNBC cells, but also of liver, prostate, and ovarian cancer cells.

Keywords


Cite This Article

APA Style
KIM, E.S., KIM, S., MOON, A. (2023). A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells. Oncology Research, 31(6), 867-875. https://doi.org/10.32604/or.2023.030411
Vancouver Style
KIM ES, KIM S, MOON A. A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells. Oncol Res. 2023;31(6):867-875 https://doi.org/10.32604/or.2023.030411
IEEE Style
E.S. KIM, S. KIM, and A. MOON "A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells," Oncol. Res., vol. 31, no. 6, pp. 867-875. 2023. https://doi.org/10.32604/or.2023.030411



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 707

    View

  • 418

    Download

  • 0

    Like

Share Link